JPH089608B2 - α，β−不飽和ケトラクトンの製造法 - Google Patents
α，β−不飽和ケトラクトンの製造法Info
- Publication number
- JPH089608B2 JPH089608B2 JP4073782A JP7378292A JPH089608B2 JP H089608 B2 JPH089608 B2 JP H089608B2 JP 4073782 A JP4073782 A JP 4073782A JP 7378292 A JP7378292 A JP 7378292A JP H089608 B2 JPH089608 B2 JP H089608B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- aldehyde
- group
- unsaturated
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- -1 bicyclolactone aldehyde Chemical class 0.000 claims abstract description 18
- 150000003752 zinc compounds Chemical class 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 5
- 150000004678 hydrides Chemical class 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 9
- 150000003180 prostaglandins Chemical class 0.000 abstract description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract description 3
- 239000007858 starting material Substances 0.000 abstract description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 abstract 1
- 150000008046 alkali metal hydrides Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 13
- 150000002596 lactones Chemical class 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- CISDEVRDMKWPCP-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluoroheptan-2-one Chemical compound CCCCC(F)(F)C(=O)CP(=O)(OC)OC CISDEVRDMKWPCP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- SQRDEVDPDGSBGC-UHFFFAOYSA-N 4,7,7-trimethyl-3-oxabicyclo[2.2.1]heptan-2-one Chemical compound C1CC2(C)OC(=O)C1C2(C)C SQRDEVDPDGSBGC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229910052716 thallium Inorganic materials 0.000 description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
- 150000003476 thallium compounds Chemical class 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- YFWYFKKSPMQIHD-MPQCRVMESA-N (3aR,4R,5R,6aS)-4-[(E)-4,4-difluoro-3-oxodec-1-enyl]-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound FC(C(/C=C/[C@@H]1[C@H]2CC(O[C@H]2C[C@H]1OC1OCCCC1)=O)=O)(CCCCCC)F YFWYFKKSPMQIHD-MPQCRVMESA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BCRKBAANNQLPBT-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluorononan-2-one Chemical compound CCCCCCC(F)(F)C(=O)CP(=O)(OC)OC BCRKBAANNQLPBT-UHFFFAOYSA-N 0.000 description 1
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BNAWBBXVVZKIRN-UHFFFAOYSA-N CCCCC(C(COP(O)=O)=O)(F)F Chemical compound CCCCC(C(COP(O)=O)=O)(F)F BNAWBBXVVZKIRN-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000006804 Parikh-Doering oxidation reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- DZFYOYRNBGNPJW-UHFFFAOYSA-N ethoxythallium Chemical compound [Tl+].CC[O-] DZFYOYRNBGNPJW-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical group CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Furan Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4073782A JPH089608B2 (ja) | 1991-04-04 | 1992-03-30 | α，β−不飽和ケトラクトンの製造法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3-71483 | 1991-04-04 | ||
| JP7148391 | 1991-04-04 | ||
| JP4073782A JPH089608B2 (ja) | 1991-04-04 | 1992-03-30 | α，β−不飽和ケトラクトンの製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0592965A JPH0592965A (ja) | 1993-04-16 |
| JPH089608B2 true JPH089608B2 (ja) | 1996-01-31 |
Family
ID=13461939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4073782A Expired - Lifetime JPH089608B2 (ja) | 1991-04-04 | 1992-03-30 | α，β−不飽和ケトラクトンの製造法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5229529A (esLanguage) |
| EP (1) | EP0507625B1 (esLanguage) |
| JP (1) | JPH089608B2 (esLanguage) |
| KR (1) | KR970003125B1 (esLanguage) |
| AT (1) | ATE141921T1 (esLanguage) |
| CA (1) | CA2064481C (esLanguage) |
| DE (1) | DE69213067T2 (esLanguage) |
| DK (1) | DK0507625T3 (esLanguage) |
| ES (1) | ES2093776T3 (esLanguage) |
| GR (1) | GR3020903T3 (esLanguage) |
| TW (1) | TW197439B (esLanguage) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994007884A1 (fr) * | 1992-09-30 | 1994-04-14 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | PROCEDE POUR PRODUIRE UNE CETONE α,β-INSATUREE |
| AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
| US20040234472A1 (en) | 2001-04-20 | 2004-11-25 | Jackson John K. | Micellar drug delivery systems for hydrophobic drugs |
| JP4358940B2 (ja) * | 1999-08-26 | 2009-11-04 | 丸善石油化学株式会社 | シクロヘキサンラクトン構造を有する重合性化合物及び重合体 |
| CA2307393A1 (en) | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US20030157170A1 (en) * | 2001-03-13 | 2003-08-21 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| EP2014307A3 (en) | 2001-03-13 | 2010-12-08 | Angiotech International Ag | Micellar drug delivery vehicles and uses thereof |
| US20030216758A1 (en) * | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
| DE10220729A1 (de) * | 2002-05-08 | 2003-11-20 | Martin Foerster | Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
| EP1633317A4 (en) | 2003-05-16 | 2008-08-20 | Intermune Inc | Synthetic chemokine receptor ligands and methods of use therefor |
| US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| US7846940B2 (en) * | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| JP2008513356A (ja) * | 2004-08-09 | 2008-05-01 | アリオス バイオファーマ インク． | 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法 |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| US8691780B2 (en) * | 2005-02-17 | 2014-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
| US20070073385A1 (en) * | 2005-09-20 | 2007-03-29 | Cook Incorporated | Eluting, implantable medical device |
| CA2819844C (en) * | 2006-02-07 | 2015-09-15 | R-Tech Ueno, Ltd. | Prostaglandin derivatives |
| ES2609388T3 (es) | 2006-03-22 | 2017-04-20 | Syncore Biotechnology Co., Ltd | Tratamiento del cáncer de mama triple negativo a receptores |
| WO2008005284A2 (en) | 2006-06-30 | 2008-01-10 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
| US20080241215A1 (en) * | 2007-03-28 | 2008-10-02 | Robert Falotico | Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke |
| US8420110B2 (en) | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
| US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
| US8273404B2 (en) | 2008-05-19 | 2012-09-25 | Cordis Corporation | Extraction of solvents from drug containing polymer reservoirs |
| WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
| EP2310507A4 (en) | 2008-07-08 | 2013-03-20 | David Gladstone Inst | METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION |
| US8642063B2 (en) | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
| US8513441B2 (en) * | 2008-08-29 | 2013-08-20 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
| US8354435B2 (en) | 2008-09-08 | 2013-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| WO2010062308A1 (en) | 2008-10-28 | 2010-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
| EP2429982A4 (en) | 2009-01-22 | 2012-09-12 | Apotex Pharmachem Inc | METHOD FOR THE PRODUCTION OF LUBIPROSTON AND INTERMEDIATE PRODUCTS THEREOF |
| WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| US20120303115A1 (en) | 2011-05-25 | 2012-11-29 | Dadino Ronald C | Expandable devices coated with a rapamycin composition |
| US20120302954A1 (en) | 2011-05-25 | 2012-11-29 | Zhao Jonathon Z | Expandable devices coated with a paclitaxel composition |
| US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
| EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
| WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| ES2653487T3 (es) | 2013-02-15 | 2018-02-07 | The Regents Of The University Of California | Receptor de antígeno quimérico y métodos de uso del mismo |
| US9670162B2 (en) | 2013-03-14 | 2017-06-06 | The Board Of Trustees Of The Leland Stanford Junio | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof |
| AU2014354643B2 (en) | 2013-11-27 | 2020-03-05 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
| AU2016326747A1 (en) | 2015-09-25 | 2018-03-01 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| EP3373977A4 (en) | 2015-11-12 | 2019-07-17 | The Board of Trustees of the Leland Stanford Junior University | CELL-PENETRATING, GUANIDINIUM-LICH OLIGOPHOSPHOTRIESTER FOR ACTIVE AND SPILL-RELIEF |
| TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
| JP7109427B2 (ja) | 2016-06-01 | 2022-07-29 | セルヴィエ アイピー ユーケー リミテッド | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
| TWI852903B (zh) | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| US12187801B2 (en) | 2017-01-18 | 2025-01-07 | Exuma Biotech Corp. | Chimeric antigen receptors against AXL or ROR2 and methods of use thereof |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| EP3630189A4 (en) | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | LINKER FOR ANTIBODY MEDICINAL CONJUGATES |
| EP3746085A4 (en) | 2018-01-31 | 2022-03-09 | Galera Labs, LLC | COMBINATION OF CANCER THERAPY USING A PENTAAZA MACROCYCLIC RING COMPLEX AND A PLATINUM-BASED ANTI-CANCER AGENT |
| EP3773633A4 (en) | 2018-04-06 | 2022-01-26 | The Regents of The University of California | METHODS OF TREATMENT OF GLIOBLASTOMA |
| EP3773632A4 (en) | 2018-04-06 | 2022-05-18 | The Regents of The University of California | Methods of treating egfrviii expressing glioblastomas |
| AU2019252676A1 (en) | 2018-04-11 | 2020-11-26 | Ohio State Innovation Foundation | Methods and compositions for sustained release microparticles for ocular drug delivery |
| US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
| WO2020148612A1 (en) | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3129883A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| BR112021019701A2 (pt) | 2019-04-02 | 2021-12-14 | Kenjockety Biotechnology Inc | Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos |
| MX2022007237A (es) | 2019-12-12 | 2022-07-13 | Ignite Immunotherapy Inc | Variante del virus de la vacuna oncolitica y metodos de uso del mismo. |
| EP4097134A1 (en) | 2020-01-29 | 2022-12-07 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
| AU2021284240A1 (en) | 2020-06-04 | 2022-12-08 | William Robert ARATHOON | Anti-ABCG2 antibodies and uses thereof |
| AU2021283080A1 (en) | 2020-06-04 | 2022-12-15 | William Robert ARATHOON | ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
| CN116133671A (zh) | 2020-07-14 | 2023-05-16 | 辉瑞公司 | 重组牛痘病毒 |
| AU2021338286A1 (en) | 2020-09-02 | 2023-03-23 | William Robert ARATHOON | Anti-ABCC1 antibodies and uses thereof |
| EP4244257A1 (en) | 2020-11-13 | 2023-09-20 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| MX2023005979A (es) | 2020-11-20 | 2023-08-11 | Scherer Technologies Llc R P | Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco. |
| WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4032576A (esLanguage) * | 1976-01-08 | 1977-06-28 | ||
| DE2655004C3 (de) * | 1976-12-02 | 1980-06-19 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von bicyclischen Laktonen |
| DE3574470D1 (en) * | 1985-09-18 | 1990-01-04 | Upjohn Co | Stereoselective reduktion. |
| JPS62153259A (ja) * | 1985-12-26 | 1987-07-08 | Sagami Chem Res Center | （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法 |
| DE3620442A1 (de) * | 1986-06-18 | 1987-12-23 | Merck Patent Gmbh | Ketolactone |
| JP2588269B2 (ja) * | 1987-09-04 | 1997-03-05 | ジ・アップジョン・カンパニー | プロスタグランジン中間体類の製法 |
-
1992
- 1992-03-28 TW TW081102387A patent/TW197439B/zh active
- 1992-03-30 JP JP4073782A patent/JPH089608B2/ja not_active Expired - Lifetime
- 1992-03-31 CA CA002064481A patent/CA2064481C/en not_active Expired - Fee Related
- 1992-04-01 US US07/861,518 patent/US5229529A/en not_active Expired - Lifetime
- 1992-04-03 DE DE69213067T patent/DE69213067T2/de not_active Expired - Fee Related
- 1992-04-03 EP EP92302992A patent/EP0507625B1/en not_active Expired - Lifetime
- 1992-04-03 AT AT92302992T patent/ATE141921T1/de not_active IP Right Cessation
- 1992-04-03 DK DK92302992.0T patent/DK0507625T3/da active
- 1992-04-03 ES ES92302992T patent/ES2093776T3/es not_active Expired - Lifetime
- 1992-04-04 KR KR1019920005662A patent/KR970003125B1/ko not_active Expired - Fee Related
-
1996
- 1996-08-29 GR GR960402124T patent/GR3020903T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR970003125B1 (ko) | 1997-03-14 |
| EP0507625A1 (en) | 1992-10-07 |
| CA2064481A1 (en) | 1992-10-05 |
| DE69213067T2 (de) | 1997-01-16 |
| DK0507625T3 (da) | 1996-09-16 |
| GR3020903T3 (en) | 1996-11-30 |
| ES2093776T3 (es) | 1997-01-01 |
| ATE141921T1 (de) | 1996-09-15 |
| EP0507625B1 (en) | 1996-08-28 |
| DE69213067D1 (de) | 1996-10-02 |
| JPH0592965A (ja) | 1993-04-16 |
| KR920019771A (ko) | 1992-11-20 |
| US5229529A (en) | 1993-07-20 |
| CA2064481C (en) | 1996-12-24 |
| TW197439B (esLanguage) | 1993-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH089608B2 (ja) | α，β−不飽和ケトラクトンの製造法 | |
| DE69526443T2 (de) | 2-silyloxy-tetrahydrothienopyridin, sein salz und verfahren zu seiner herstellung | |
| JP3298929B2 (ja) | カルボン酸エステル又はカルボン酸チオエステルの新規製造方法 | |
| HU226413B1 (en) | Novel 16-(nitro-substituted methyl)pregna-1,4-dien-3,20-dion derivatives and process for producing them | |
| JP3135658B2 (ja) | ラクトン誘導体の新規製造方法 | |
| US5468880A (en) | Method of producing α, β-unsaturated ketones | |
| JP2746800B2 (ja) | プロスタグランジン中間体の製法 | |
| JP2608458B2 (ja) | ４−アセトキシアゼチジノン誘導体の製造法 | |
| JPH10130244A (ja) | アシクロヌクレオシドの製造方法 | |
| JP2602669B2 (ja) | ２β−ハロゲノ置換メチルペニシリン誘導体の製造法 | |
| KR940006531B1 (ko) | 피리딘 유도체의 제조방법 | |
| US3886185A (en) | Novel prostaglandin intermediates and process for the production thereof | |
| US4808340A (en) | Process for preparing methyl 4-oxo-5-tetradecynoate | |
| US5079371A (en) | Process for production of prostaglandin intermediates | |
| JP2980992B2 (ja) | ６−ハロゲノ−２−オキサプレグナ−４，６−ジエン−３−オン化合物の製造方法 | |
| CA1095032A (en) | Mono-deuterated, 15-hydroxyprostaglandins | |
| US4140863A (en) | 9,11-Dihalo-PG2 compounds | |
| JP3266701B2 (ja) | ２，３−ジヒドロポリプレノールの製造法 | |
| KR810001248B1 (ko) | 시클로펜탄올의 락톤유도체의 제조방법 | |
| JP2664841B2 (ja) | ６，７―二置換―２―ヒドロキシ―３―メチレンビシクロ［３．３．０］オクタン類の製造法 | |
| JP2000044537A (ja) | ４−置換アゼチジニルペンタン酸誘導体の製造法 | |
| JP2581186B2 (ja) | ４−置換−２−シクロペンテノンエステル誘導体の製造法 | |
| JPS5822020B2 (ja) | シクロペンタノンカルボンサンエステルユウドウタイノセイホウ | |
| JPH05271148A (ja) | 光学活性α−ヒドロオキシカルボン酸の製造方法 | |
| JPH0316942B2 (esLanguage) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080131 Year of fee payment: 12 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080131 Year of fee payment: 12 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080131 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090131 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090131 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100131 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100131 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110131 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110131 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120131 Year of fee payment: 16 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130131 Year of fee payment: 17 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130131 Year of fee payment: 17 |